SWOG clinical trial number
SWOG-8921

Trials of Cyclophosphamide, IL-2, DTIC/IL-2, and DTIC/Cisplatin/Tamoxifen in Stage IV Melanoma

Closed
Phase
Accrual
100%
Published
Abbreviated Title
Trials of Cyclophosphamide, IL-2, DTIC/IL-2, and DTIC/Cisplatin/Tamoxifen in Stage IV Melanoma
Activated
02/15/1990
Closed
09/01/1991

Research committees

Melanoma

Publication Information Expand/Collapse

2008

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. [PMID18235113]

EL Korn;PY Liu;SJ Lee;JAW Chapman;D Niedzwiecki;VJ Suman;J Moon;VK Sondak;MB Atkins;EA Eisenhauer;W Parulekar;SN Markovic;S Saxman;JM Kirkwood Journal of Clinical Oncology 26(4):527-534

2001

Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials

JM Unger;LE Flaherty;PY Liu;KS Albain;VK Sondak Cancer 91(6):148-1155

1997

Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma.

LE Flaherty;PY Liu;JM Unger;VK Sondak American Journal of Clinical Oncology 20(6):600-604

1996

The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group (SWOG-8921).

LE Flaherty;PY Liu;MS Mitchell;WS Fletcher;MJ Walker;JW Goodwin;RL Stephens;VK Sondak American Journal of Clinical Oncology 19(2):108-113

1995

Survival and response to treatment in patients (pts) with metastatic melanoma from intraocular primaries (MMIP) on SWOG studies.

K Katato;PY Liu;V Sondak;LE Flaherty ASCO 14:410(#1298)

1994

Comparison of patient characteristics and outcome between a single institution and cooperative group phase II trial in metastatic melanoma with identical eligibility

L Flaherty;M Hussein;PY Liu;D Smith;V Sondak ASCO 13:397(#1352)

1993

The addition of tamoxifen (T) to dacarbazine (D) and cisplatin (C) in a Southwest Oncology Group phase II trial (8921) in metastatic malignant melanoma (MMM) stage IV.

L Flaherty;PY Liu;D Daniels;V Sondak ASCO 12:394(#1349)

1992

Dacarbazine and outpatient Interleukin-2 in treatment of metastatic malignant melanoma: Phase II Southwest Oncology Group trial.

LE Flaherty;PY Liu;WS Fletcher;JW Goodwin;SP Balcerzak;D Daniels;RL Stephens;V Sondak JNCI 84(11):893-894

Other Clinical Trials

SWOG Clinical Trial Number
S2000

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases
Research Committee(s)
Melanoma
Activated
09/23/2020
Accrual
91%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6174

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Research Committee(s)
Melanoma
Activated
10/01/2018
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6141

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Research Committee(s)
Melanoma
Activated
09/10/2015
Open
Phase